BXBuri Xi

Buri Xi

*This is an algorithmically generated author record based on publicly available information.

Buri Xi has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Ahmed Ashour Ahmed

    MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom

    1 shared publication
  • Guanglei Zhuang

    State Key Laboratory of Systems Medicine for Cancer, Shanghai Key Laboratory of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine

    1 shared publication
  • Hai Gong

    Institute of Cyber-Systems and Control, College of Control Science and Engineering, Zhejiang University

    1 shared publication
  • Junxiu Chen

    HIO Technology (Huzhou) Ltd

    1 shared publication
  • Li Ye

    Department of Colorectal Surgery and Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine

    1 shared publication
  • Longxia Li

    Institute for Ovarian Cancer, Fudan University and Department of Gynecologic Oncology, Zhongshan Hospital, Fudan University

    1 shared publication

Latest Publications

  • Open Access

    The p38α MAPK–MK2 axis drives chemotherapy-mediated nuclear actin remodeling to promote ovarian cancer progression

    by Xiaoxia Xing, Zhihao Zhang, Longxia Li, Zhouying Shen, Buri Xi, Yixuan Yang, Min Diao, Li Ye, Junxiu Chen, Guanglei Zhuang, et al.

    Nuclear F-actin facilitates DNA damage repair and contributes to cancer chemoresistance. However, the regulatory mechanisms controlling its dynamic polymerization in response to genotoxic stress remain poorly defined. A major barrier in nuclear actin research is the lack of tools for precise, high-throughput analysis. To systematically investigate nuclear F-actin assembly in DNA damage response, we developed a deep learning pipeline, named nFANet, for high-throughput detection and analysis of nuclear F-actin. Here, using ovarian cancer—a malignancy where chemoresistance is a major clinical obstacle—as a model, we showed that platinum-based chemotherapy robustly induces nuclear F-actin assembly. A subsequent kinome screening, in combination with the application of nFANet, identified the kinase p38α MAPK as a critical upstream regulator of platinum-induced nuclear F-actin assembly. Mechanistically, the p38α MAPK–MK2 signaling pathway promotes formin-mediated nuclear F-actin assembly in response to chemotherapy. Importantly, pharmacological inhibition or genetic knockout of the p38α MAPK–MK2 pathway sensitized ovarian cancer cells to platinum-based therapy. Our work uncovers a key mechanism governing nuclear actin remodeling under genotoxic stress and lays the foundation for identifying a patient subgroup likely to benefit from therapeutic targeting of this pathway.